Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Foundation Medicine Extends and Expands Collaboration with Novartis

Published: Wednesday, January 08, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Collaboration will now extend through at least September 2016.

Foundation Medicine has announced that it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis' clinical oncology programs.

As the result of Foundation Medicine and Novartis' pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicine's comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis' oncology clinical trials.

This new agreement, which the companies agreed to extend and expand prior to the end of the existing term, includes committed capacity for Foundation Medicine to provide genomic profiling of patient samples from Novartis clinical trials, as well as access to Foundation Medicine's molecular information and analysis services.

The new three-year agreement also gives Novartis the option to extend the term for an additional two-year period. Financial terms are not being disclosed.

"We are deeply committed to our relationship with Novartis and pleased with the continued growth of our collaboration," said Michael J. Pellini, M.D., president and CEO, Foundation Medicine.

Pellini continued, "In addition to providing comprehensive genomic profiling for patients in Novartis clinical trials, this expanded agreement will allow Novartis to take advantage of our unique and growing database of molecular information to support the evaluation and development of Novartis' oncology drug candidates, biological targets and clinical trials."

Foundation Medicine uses comprehensive, clinical grade next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers.

Novartis uses these capabilities to support its targeted therapy clinical development efforts by helping to align the genomic profile of individual patient's cancer with clinical trial enrollment criteria and clinical outcome analysis.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine, IMS Health Collaborate
IMS Health will combine its Real-World Evidence platform with Foundation Medicine's FoundationCore knowledge base, enabling clients to interpret real-world oncology outcomes, the firms said today.
Tuesday, June 23, 2015
Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China.
Friday, October 31, 2014
Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.
Friday, May 03, 2013
Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration
Collaboration seeks to enhance clinical trial design by identifying genomic predictors of response to targeted cancer therapies.
Monday, November 12, 2012
Foundation Medicine Announces $42.5 Million Series B Financing
Syndicate includes leading public and strategic investors; proceeds will expand commercial operations and accelerate adoption of FoundationOne™.
Monday, October 01, 2012
Foundation Medicine Enters Extensive Collaboration with Novartis
Pilot agreement extended to a broad financial commitment over three years.
Monday, June 11, 2012
Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
Findings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Tuesday, February 14, 2012
Foundation Medicine Receives CLIA Certification for Its Genomic Sequencing Laboratory
This certification follows receipt of a Massachusetts State license and allows the company to accept clinical samples from most U.S. states.
Friday, February 03, 2012
Foundation Medicine Announces Collaboration with Sanofi
Fifth partnership will help translate cancer genomic science to clinical results. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.
Friday, January 13, 2012
Foundation Medicine Appoints Molecular Diagnostics Industry Leader Maureen T. Cronin, Ph.D., as Senior Vice President of Research and Product Development
Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, have announced the appointment of Maureen T. Cronin, Ph.D., to the newly created position of senior vice president, research and product development.
Tuesday, November 16, 2010
Scientific News
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!